Black Diamond Therapeutic Stock (NASDAQ: BDTX)

Black Diamond Therapeutic

BLACK DIAMOND THERAPEUTICS I

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Suresnes,,France,-,July,8,,2024:,A,View,Of,The

Biotech

News

Health Care

Contracts

General

BDTX

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics&#39; BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone payments.

Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million

movers image

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

ATPC

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

TRAW

VMAR

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

Black Diamond Therapeutics&#39; Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca&#39;s Drug

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutics Inc

Press Releases

Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Management

NAYA Biosciences Announces Nomination of New Board Members

Earnings

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

BATL

BNZI

KAVL

KYMR

NAYA

PRSO

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Agenus

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Cellectis S.A. - American Depositary Shares

Cellectis

Editas Medicine

Elicio Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

I-MAB

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

RAPT Therapeutics

AVITA Medical

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Spero Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

HC Wainwright & Co.

Stifel

Wedbush

Piper Sandler

Raymond James

Comments

Black Diamond Therapeutic

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell